Entering text into the input field will update the search result below

Expanded use of Shire's CINRYZE OK'd in Europe

Mar. 16, 2017 7:27 AM ETShire PLC (SHPG) StockBy: Douglas W. House, SA News Editor
  • The European Medicines Agency approves expanded indications for Shire plc's (NASDAQ:SHPG) hereditary angioedema (HAE) med CINRYZE (C1 inhibitor [human]).
  • The product is now approved for routine prevention of angioedema attacks in children as young as six years with severe and recurrent attacks of HAE who are intolerant of or inadequately protected by oral preventative treatments or who are inadequately managed with repeated acute treatment. It is also approved for the treatment and pre-procedure prevention of angioedema attacks in children as young as two years with HAE.
  • CNRYZE, developed by ViroPharma, was first approved in the EU in June 2011. Shire announced its $4.2B acquisition of the company in November 2013.
  • Shares are up a fraction premarket.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SHPG--
Shire PLC